Table 3 Risk factors for local recurrence by Cox proportional hazard regression analysis
Factor | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
Age | 0.069 | |||||
≤ 40 | 2.90 | 0.92–9.15 | ||||
> 40 | 1.00 | |||||
MRI findings | 0.520 | |||||
Segmental lesion | 1.00 | |||||
Isolated mass | 1.96 | 0.25–15.37 | ||||
Histology | 0.423 | |||||
DCIS/LCIS | 1.00 | |||||
IDC/ILC | 0.56 | 0.13–2.34 | ||||
Tumor size | 0.507 | |||||
Is | 1.00 | |||||
1 | 0.66 | 0.15–2.95 | ||||
2/3 | 0.62 | 0.34–6.13 | ||||
Nodal status | 0.294 | |||||
− | 1.00 | |||||
+ | 1.90 | 0.57–6.32 | ||||
Stage | 0.849 | |||||
0 | 1.00 | |||||
I | 0.80 | 0.18–3.60 | ||||
II/III | 1.18 | 0.28–4.97 | ||||
ER | 0.482 | |||||
+ | 1.00 | |||||
− | 1.61 | 0.42–6.04 | ||||
PgR | 0.965 | |||||
+ | 1.00 | 0.28–3.44 | ||||
− | 0.97 | |||||
HER2 | 0.776 | |||||
+ | 1.00 | |||||
− | 0.82 | 0.21–3.19 | ||||
Subtype | 0.526 | |||||
Luminal A-like | 1.00 | |||||
Luminal B-like HER2 negative | 2.24 | 0.55–9.06 | ||||
Luminal B-like HER2 positive/HER2 | 1.56 | 0.38–6.48 | ||||
EIC | 0.927 | |||||
+ | 0.94 | 0.23–3.77 | ||||
− | 1.00 | |||||
Lymphatic vessel invasion | 0.005 | 0.017 | ||||
+ | 6.60 | 1.78–24.47 | 6.63 | 1.40–31.36 | ||
− | 1.00 | |||||
Nuclear grade | 0.518 | |||||
Low/intermediate/high grade DCIS | 1.00 | |||||
1 | 0.75 | 0.12–4.60 | ||||
2/3 | 1.64 | 0.33–8.16 | ||||
Operation | 0.905 | |||||
TM/SSM | 1.00 | |||||
NSM | 1.43 | 0.17–11.88 | ||||
ASM | 1.44 | 0.18–11.45 | ||||
Surgical margin (lateral) | 0.568 | |||||
+ , < 2 mm | 1.82 | 0.23–14.24 | ||||
− | 1.00 | |||||
Surgical margin (vertical) | 0.018 | 0.031 | ||||
+ , < 2 mm | 10.58 | 1.32–84.64 | 9.72 | 1.23–77.13 | ||
− | 1.00 | 1.00 | ||||
Adjuvant hormonal therapy | 0.402 | |||||
+ | 0.61 | 0.19–1.94 | ||||
− | 1.00 | |||||
Any chemotherapy ± Trastuzumab | 0.650 | |||||
+ | 1.31 | 0.41–4.16 | ||||
− | 1.00 | |||||